Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen Versus Aspirin in Endovascular Unruptured Intracranial Aneurysms Treatment
NCT07089862Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2025
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised trial of Indobufen in brain aneurysm (IA) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Cerebrovascular thromboembolic events at 90 days and Incidence of bleeding events at 90 days. Started Aug 2025; status: recruiting.
02
Drugs
Indobufen
03
Conditions
brain aneurysm (IA)
Beyond the preview
Go deeper on NCT07089862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089862.